Functionality of Probiotics – Potential for Product Development

It is becoming increasingly accepted by consumers that live lactic acid bacteria do exert health benefits when eaten. In addition, it is also becoming recognised that not all probiotic bacteria are equal. It is now no longer just a question of providing sufficient numbers of viable bacteria in a pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Forum of nutrition 2007-01, Vol.60, p.196-208
Hauptverfasser: Dekker, James, Collett, Michael, Prasad, Jaya, Gopal, Pramod
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 208
container_issue
container_start_page 196
container_title Forum of nutrition
container_volume 60
creator Dekker, James
Collett, Michael
Prasad, Jaya
Gopal, Pramod
description It is becoming increasingly accepted by consumers that live lactic acid bacteria do exert health benefits when eaten. In addition, it is also becoming recognised that not all probiotic bacteria are equal. It is now no longer just a question of providing sufficient numbers of viable bacteria in a product; industry must also provide proof of efficacy for each strain. In the early 1990s, Fonterra embarked on a programme to develop proprietary probiotic strains, and as a result, commercialised two strains, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001. Over the past decade, Fonterra has developed a significant body of peerreviewed published reports around these strains, including studies showing safety in animal and human trials, protection against pathogens such as Salmonella typhimurium and Escherichia coli O157:H7, modulation of human and animal immune markers at realistic dose rates, and efficacy in human clinical trials. Based on this work, HN019 and HN001 have been applied to several functional foods both by Fonterra (under the DR10™ and DR20™ brands, respectively) and by third parties (e.g. under the HOWARU™ brand by Danisco). While the ‘gold standard’ of proof of efficacy is a phase III clinical trial, ethical considerations as well as expense preclude the use of clinical trials as screening tools for probiotics. Therefore, biomarkers have to be employed to identify strains with probiotic utility, and to define the different positive health benefits of existing probiotic strains. However, as the mechanisms by which most probiotic bacteria exert their health benefits remain unclear, the question of which biomarkers accurately reflect efficacy in vivo remains unresolved. With recent technological advances, and the shift toward probiotics targeted to specific conditions, researchers are beginning to tease out how probiotic bacteria work, and it is this knowledge that will inform biomarker development and improve the ability to offer the market safe and effective probiotic functional foods.
doi_str_mv 10.1159/000107196
format Article
fullrecord <record><control><sourceid>pubmed_karge</sourceid><recordid>TN_cdi_karger_ebooksseries_107196</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17684416</sourcerecordid><originalsourceid>FETCH-LOGICAL-c235t-2f2dbfe87e91de27e97db1c7dd3042ac0ce307a3e5e5d32fd312f6782d1a31883</originalsourceid><addsrcrecordid>eNqFkLtOwzAYhc1NFJUOvAAKA2PAv534MlaFAlIlOsAcOfZvFJrWUZwideMdeEOehEBgZjrD9-lI5xByBvQKINfXlFKgErTYIxMtFeegKGRa031yAkKwlGklDwamaJ4rBoId_jCaUp7JEZnE-NrXUKGF5OyYjEAKlWUgTsh0vt3YrgobU1fdLgk-WbahrEJX2Zh8vn8ky9DhpqtMnfjQfkO3tV1yg29Yh2bdo1Ny5E0dcfKbY_I8v32a3aeLx7uH2XSRWsbzLmWeudKjkqjBIetDuhKsdI7TjBlLLXIqDcccc8eZdxyYF1IxB6afrPiYnA-9zbZcoyuatlqbdlf8bemFi0FYmfYF2wLLEFYxYlthLIYLe-fyP6donOdfsgBqIw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Functionality of Probiotics – Potential for Product Development</title><source>MEDLINE</source><source>Karger Book Series</source><creator>Dekker, James ; Collett, Michael ; Prasad, Jaya ; Gopal, Pramod</creator><contributor>Tai ES ; Gillies PJ</contributor><creatorcontrib>Dekker, James ; Collett, Michael ; Prasad, Jaya ; Gopal, Pramod ; Tai ES ; Gillies PJ</creatorcontrib><description>It is becoming increasingly accepted by consumers that live lactic acid bacteria do exert health benefits when eaten. In addition, it is also becoming recognised that not all probiotic bacteria are equal. It is now no longer just a question of providing sufficient numbers of viable bacteria in a product; industry must also provide proof of efficacy for each strain. In the early 1990s, Fonterra embarked on a programme to develop proprietary probiotic strains, and as a result, commercialised two strains, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001. Over the past decade, Fonterra has developed a significant body of peerreviewed published reports around these strains, including studies showing safety in animal and human trials, protection against pathogens such as Salmonella typhimurium and Escherichia coli O157:H7, modulation of human and animal immune markers at realistic dose rates, and efficacy in human clinical trials. Based on this work, HN019 and HN001 have been applied to several functional foods both by Fonterra (under the DR10™ and DR20™ brands, respectively) and by third parties (e.g. under the HOWARU™ brand by Danisco). While the ‘gold standard’ of proof of efficacy is a phase III clinical trial, ethical considerations as well as expense preclude the use of clinical trials as screening tools for probiotics. Therefore, biomarkers have to be employed to identify strains with probiotic utility, and to define the different positive health benefits of existing probiotic strains. However, as the mechanisms by which most probiotic bacteria exert their health benefits remain unclear, the question of which biomarkers accurately reflect efficacy in vivo remains unresolved. With recent technological advances, and the shift toward probiotics targeted to specific conditions, researchers are beginning to tease out how probiotic bacteria work, and it is this knowledge that will inform biomarker development and improve the ability to offer the market safe and effective probiotic functional foods.</description><identifier>ISSN: 1660-0347</identifier><identifier>ISBN: 9783805582162</identifier><identifier>ISBN: 3805582161</identifier><identifier>EISSN: 1662-2987</identifier><identifier>EISBN: 9783318014990</identifier><identifier>EISBN: 3318014990</identifier><identifier>DOI: 10.1159/000107196</identifier><identifier>PMID: 17684416</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Animals ; Antibiosis ; Bifidobacterium - physiology ; Biomarkers - analysis ; Chapter ; Colony Count, Microbial ; Consumer Product Safety ; Escherichia coli O157 - growth &amp; development ; Food Microbiology ; Food, Organic ; Humans ; Lactobacillus - physiology ; Probiotics</subject><ispartof>Forum of nutrition, 2007-01, Vol.60, p.196-208</ispartof><rights>2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c235t-2f2dbfe87e91de27e97db1c7dd3042ac0ce307a3e5e5d32fd312f6782d1a31883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,775,776,780,789,26059,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17684416$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Tai ES</contributor><contributor>Gillies PJ</contributor><creatorcontrib>Dekker, James</creatorcontrib><creatorcontrib>Collett, Michael</creatorcontrib><creatorcontrib>Prasad, Jaya</creatorcontrib><creatorcontrib>Gopal, Pramod</creatorcontrib><title>Functionality of Probiotics – Potential for Product Development</title><title>Forum of nutrition</title><addtitle>Forum Nutr</addtitle><description>It is becoming increasingly accepted by consumers that live lactic acid bacteria do exert health benefits when eaten. In addition, it is also becoming recognised that not all probiotic bacteria are equal. It is now no longer just a question of providing sufficient numbers of viable bacteria in a product; industry must also provide proof of efficacy for each strain. In the early 1990s, Fonterra embarked on a programme to develop proprietary probiotic strains, and as a result, commercialised two strains, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001. Over the past decade, Fonterra has developed a significant body of peerreviewed published reports around these strains, including studies showing safety in animal and human trials, protection against pathogens such as Salmonella typhimurium and Escherichia coli O157:H7, modulation of human and animal immune markers at realistic dose rates, and efficacy in human clinical trials. Based on this work, HN019 and HN001 have been applied to several functional foods both by Fonterra (under the DR10™ and DR20™ brands, respectively) and by third parties (e.g. under the HOWARU™ brand by Danisco). While the ‘gold standard’ of proof of efficacy is a phase III clinical trial, ethical considerations as well as expense preclude the use of clinical trials as screening tools for probiotics. Therefore, biomarkers have to be employed to identify strains with probiotic utility, and to define the different positive health benefits of existing probiotic strains. However, as the mechanisms by which most probiotic bacteria exert their health benefits remain unclear, the question of which biomarkers accurately reflect efficacy in vivo remains unresolved. With recent technological advances, and the shift toward probiotics targeted to specific conditions, researchers are beginning to tease out how probiotic bacteria work, and it is this knowledge that will inform biomarker development and improve the ability to offer the market safe and effective probiotic functional foods.</description><subject>Animals</subject><subject>Antibiosis</subject><subject>Bifidobacterium - physiology</subject><subject>Biomarkers - analysis</subject><subject>Chapter</subject><subject>Colony Count, Microbial</subject><subject>Consumer Product Safety</subject><subject>Escherichia coli O157 - growth &amp; development</subject><subject>Food Microbiology</subject><subject>Food, Organic</subject><subject>Humans</subject><subject>Lactobacillus - physiology</subject><subject>Probiotics</subject><issn>1660-0347</issn><issn>1662-2987</issn><isbn>9783805582162</isbn><isbn>3805582161</isbn><isbn>9783318014990</isbn><isbn>3318014990</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOwzAYhc1NFJUOvAAKA2PAv534MlaFAlIlOsAcOfZvFJrWUZwideMdeEOehEBgZjrD9-lI5xByBvQKINfXlFKgErTYIxMtFeegKGRa031yAkKwlGklDwamaJ4rBoId_jCaUp7JEZnE-NrXUKGF5OyYjEAKlWUgTsh0vt3YrgobU1fdLgk-WbahrEJX2Zh8vn8ky9DhpqtMnfjQfkO3tV1yg29Yh2bdo1Ny5E0dcfKbY_I8v32a3aeLx7uH2XSRWsbzLmWeudKjkqjBIetDuhKsdI7TjBlLLXIqDcccc8eZdxyYF1IxB6afrPiYnA-9zbZcoyuatlqbdlf8bemFi0FYmfYF2wLLEFYxYlthLIYLe-fyP6donOdfsgBqIw</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Dekker, James</creator><creator>Collett, Michael</creator><creator>Prasad, Jaya</creator><creator>Gopal, Pramod</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20070101</creationdate><title>Functionality of Probiotics – Potential for Product Development</title><author>Dekker, James ; Collett, Michael ; Prasad, Jaya ; Gopal, Pramod</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c235t-2f2dbfe87e91de27e97db1c7dd3042ac0ce307a3e5e5d32fd312f6782d1a31883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Antibiosis</topic><topic>Bifidobacterium - physiology</topic><topic>Biomarkers - analysis</topic><topic>Chapter</topic><topic>Colony Count, Microbial</topic><topic>Consumer Product Safety</topic><topic>Escherichia coli O157 - growth &amp; development</topic><topic>Food Microbiology</topic><topic>Food, Organic</topic><topic>Humans</topic><topic>Lactobacillus - physiology</topic><topic>Probiotics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dekker, James</creatorcontrib><creatorcontrib>Collett, Michael</creatorcontrib><creatorcontrib>Prasad, Jaya</creatorcontrib><creatorcontrib>Gopal, Pramod</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Forum of nutrition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dekker, James</au><au>Collett, Michael</au><au>Prasad, Jaya</au><au>Gopal, Pramod</au><au>Tai ES</au><au>Gillies PJ</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Functionality of Probiotics – Potential for Product Development</atitle><jtitle>Forum of nutrition</jtitle><addtitle>Forum Nutr</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>60</volume><spage>196</spage><epage>208</epage><pages>196-208</pages><issn>1660-0347</issn><eissn>1662-2987</eissn><isbn>9783805582162</isbn><isbn>3805582161</isbn><eisbn>9783318014990</eisbn><eisbn>3318014990</eisbn><abstract>It is becoming increasingly accepted by consumers that live lactic acid bacteria do exert health benefits when eaten. In addition, it is also becoming recognised that not all probiotic bacteria are equal. It is now no longer just a question of providing sufficient numbers of viable bacteria in a product; industry must also provide proof of efficacy for each strain. In the early 1990s, Fonterra embarked on a programme to develop proprietary probiotic strains, and as a result, commercialised two strains, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001. Over the past decade, Fonterra has developed a significant body of peerreviewed published reports around these strains, including studies showing safety in animal and human trials, protection against pathogens such as Salmonella typhimurium and Escherichia coli O157:H7, modulation of human and animal immune markers at realistic dose rates, and efficacy in human clinical trials. Based on this work, HN019 and HN001 have been applied to several functional foods both by Fonterra (under the DR10™ and DR20™ brands, respectively) and by third parties (e.g. under the HOWARU™ brand by Danisco). While the ‘gold standard’ of proof of efficacy is a phase III clinical trial, ethical considerations as well as expense preclude the use of clinical trials as screening tools for probiotics. Therefore, biomarkers have to be employed to identify strains with probiotic utility, and to define the different positive health benefits of existing probiotic strains. However, as the mechanisms by which most probiotic bacteria exert their health benefits remain unclear, the question of which biomarkers accurately reflect efficacy in vivo remains unresolved. With recent technological advances, and the shift toward probiotics targeted to specific conditions, researchers are beginning to tease out how probiotic bacteria work, and it is this knowledge that will inform biomarker development and improve the ability to offer the market safe and effective probiotic functional foods.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>17684416</pmid><doi>10.1159/000107196</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1660-0347
ispartof Forum of nutrition, 2007-01, Vol.60, p.196-208
issn 1660-0347
1662-2987
language eng
recordid cdi_karger_ebooksseries_107196
source MEDLINE; Karger Book Series
subjects Animals
Antibiosis
Bifidobacterium - physiology
Biomarkers - analysis
Chapter
Colony Count, Microbial
Consumer Product Safety
Escherichia coli O157 - growth & development
Food Microbiology
Food, Organic
Humans
Lactobacillus - physiology
Probiotics
title Functionality of Probiotics – Potential for Product Development
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A24%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Functionality%20of%20Probiotics%20%E2%80%93%20Potential%20for%20Product%20Development&rft.jtitle=Forum%20of%20nutrition&rft.au=Dekker,%20James&rft.date=2007-01-01&rft.volume=60&rft.spage=196&rft.epage=208&rft.pages=196-208&rft.issn=1660-0347&rft.eissn=1662-2987&rft.isbn=9783805582162&rft.isbn_list=3805582161&rft_id=info:doi/10.1159/000107196&rft_dat=%3Cpubmed_karge%3E17684416%3C/pubmed_karge%3E%3Curl%3E%3C/url%3E&rft.eisbn=9783318014990&rft.eisbn_list=3318014990&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17684416&rfr_iscdi=true